BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:[ U.S. CDMRP – Melanoma Research Program Translational Research 
 Award | Research Funding ]
DTSTART;VALUE=DATE:20200622
DTSTAMP:20260408T071412Z
UID:d76a3804f7b18516b0a6f181c0053b3c4c6113881c0332c358cd204f
CATEGORIES:Call for proposal
DESCRIPTION:Aim: Through the Congressionally Directed Medical Research Pro
 gram (CDMRP)\, the Department of Defense is announcing the Melanoma Resear
 ch Program (MRP) Awards. The MRP Translational Research Award supports hyp
 othesis-driven\, translational\, high-impact research. The TRA mechanism e
 ncourages applications with mature research projects that specifically foc
 us on critical scientific or clinical melanoma issues\, which\, if success
 fully addressed\, have the potential to make a major impact. Important fac
 tors under consideration will be continuity of research\, clinical applica
 bility\, and leveraging of clinical samples from clinical trials and/or bi
 orepositories.\n\nThe critical components of this award mechanism are:\n\n
 	Translation: The TRA is intended to support research that demonstrates th
 e potential to have a major impact on an area of paramount importance in m
 elanoma.\n	Preliminary Data: The TRA is intended to support translational 
 investigations that leapfrog the melanoma research field forward by utiliz
 ing previous research findings.\n	Correlative Research: Studies funded by 
 the TRA should leverage clinical samples from established biobanks\, biore
 positories\, and/or ongoing or completed clinical trials.\n	Collaborator O
 ption: As a method to facilitate progress in addressing critical problems 
 or questions through collaborative efforts\, the FY20 MRP is offering a Co
 llaborator Option for this award mechanism. The Collaborator Option is str
 uctured so that two investigators\, each of whom will be designated as a P
 I\, work synergistically on a single project.\n\n \nTo be considered for 
 funding\, applications must address at least one of the FY20 MRP Focus Are
 as\, which are listed at the end of this announcement\n\nFunding:     
    max. $600’000 (single PI)\, $700’000 (collaborator option)\n\nDur
 ation:      3 years\n\nEligibility: Applicants from international orga
 nizations or institutions are eligible to apply\, and there are no citizen
 ship restrictions. PI applicants must be independent investigators at or a
 bove the level of Assistant Professor (or equivalent).\n\nHow to Apply: Pr
 e-applications are submitted through the eBRAP platform. They should conta
 in contact information\, a preproposal narrative\, and a list of collabora
 tors and key personnel as suggested on the platform. Full applications (by
  invitation) will be made via a Grants.gov workspace. Full application pac
 kages can be downloaded from Grants.gov at any time.\n\nPre-Application De
 adline: 22-June-2020\, 5:00 p.m. EST\nFull Application Deadline: 24-Septem
 ber-2020\, 11:59 p.m. EST\n\nGrants.gov Funding Opportunity Number: W81XWH
 -20-MRP-TRA\n\nFurther information\n\n\n	To see the program announcement\,
  navigate to the search page on Grants.gov and search for the Opportunity 
 Number W81XWH-20-MRP-TRA\n	For questions about the eBRAP or Grants.gov pla
 tforms\, contact the Research Office.\n\n\nFY20 Focus Areas\n\n\n	Preventi
 on of melanoma initiation factors (e.g.\, UV radiation)\n	Prevention of me
 lanomagenesis and precursor lesions (e.g.\, novel genetic and epigenetic d
 rivers\, oncogene induced senescence)\n	Understanding the tumor microenvir
 onment\n	Bioengineering (e.g.\, computational\, imaging) approaches to add
 ress diagnostics\, high risk markers\, dormancy\, and metastasis\n	Therape
 utic Prevention (e.g.\, interruption of disease progression\, recurrence)\
 n	Minimal Residual Disease (e.g.\, chemoprevention\, micro-metastasis)\n
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR